Brief: TCR2 Therapeutics To Be Streamlined With About 40% Reduction In Workforce

TCR2 Therapeutics

05/01/2023 14:29

Jan 5 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR2 THERAPEUTICS INC - COMPANY TO BE STREAMLINED WITH
APPROXIMATELY 40 PERCENT REDUCTION IN WORKFORCE
    * TCR2 THERAPEUTICS INC - EXPECTED CASH RUNWAY EXTENDED INTO
EARLY
2025 DUE TO COST SAVINGS
    * TCR2 THERAPEUTICS INC - GAVO-CEL PHASE 2 CLINICAL TRIAL
NOW
FOCUSED ON OVARIAN CANCER COHORT WITH FIRST MEANINGFUL
DURABILITY DATA EXPECTED IN 2H 2023
    * TCR2 THERAPEUTICS INC - SECOND-GENERATION ENHANCED
PROGRAMS
TC-510 AND TC-520 PRIORITIZED WITH TC-510 PHASE 1 CLINICAL TRIAL
ONGOING

Source text for Eikon:  ID:nGNXhMxKK 
Further company coverage:  TCRR.O 
 ((Reuters.Briefs@thomsonreuters.com;))